MTEX MANNATECH INC
Data as of close
Healthcare · Medicinal Chemicals & Botanical Products
MANNATECH INC (MTEX) is a healthcare company in the Medicinal Chemicals & Botanical Products industry, with a market capitalization of $16 million. Shares last traded at $8.23, 33.6% below their 52-week high. Over the past year the stock is down 11.0%. Net profit margin is -6.9%, above the peer median of -8.8%. Revenue declined 8.3% year over year. The shares yield 9.7% in dividends.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.
MTEX Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2023-12-31 | $1M | $0.00 | — |
| 2022-12-31 | $2M | $0.00 | — |
| 2021-12-31 | $4M | $0.00 | 44% |
| 2020-12-31 | $3M | $0.00 | 54% |
| 2019-12-31 | $1M | $0.00 | 36% |
| 2018-12-31 | $3M | $0.00 | — |
| 2017-12-31 | $1M | $0.00 | — |
| 2016-12-31 | $1M | $0.00 | — |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $0.53 | 2026-08-12 |
| Q1 2026 | $0.49 | 2026-05-14 |
| Q4 2025 (derived) | -$5.94 | 2026-04-15 |
| FY 2025 | -$8.00 | 2026-04-15 |
| Q3 2025 | $1.01 | 2025-11-12 |
| Q2 2025 | -$2.27 | — |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Medicinal Chemicals & Botanical Products peers
MTEX vs 14 industry peers (Medicinal Chemicals & Botanical Products), by market cap. Data as of close
| DFTX | Definium Therapeutics, Inc. | $4.4B | — | — | — | -10.70% |
| RGC | Regencell Bioscience Holdings Ltd | $3.1B | — | — | — | -5.00% |
| TRLV | Trulieve Cannabis Corp. | $2.1B | — | 1.88 | -41.8% | +8.19% |
| CRON | Cronos Group | $1.2B | 17.64 | 6.89 | 39.1% | +1.52% |
| TLRY | Tilray Brands | $375M | — | 0.39 | -17.1% | +0.40% |
| SNDL | SNDL Inc. | $337M | — | — | — | +2.81% |
| CGC | Canopy Growth | $288M | — | 1.37 | -80.0% | +4.07% |
| USNA | USANA HEALTH SCIENCES INC | $271M | — | 0.30 | -2.4% | +2.69% |
| ACB | Aurora Cannabis | $237M | — | — | — | +3.94% |
| GLAS | Glass House Brands Inc. | $192M | — | 1.05 | -16.3% | +6.85% |
| NAGE | Niagen Bioscience, Inc. | $190M | 11.88 | 1.47 | 12.4% | +2.56% |
| MDWD | MediWound Ltd. | $173M | — | — | — | +1.35% |
| FTLF | FITLIFE BRANDS, INC. | $78M | 12.45 | 0.77 | 6.2% | +4.69% |
| BTMD | biote Corp. | $33M | 5.56 | 0.18 | 3.2% | +1.79% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.